| Literature DB >> 30895459 |
Simon Rauch1,2,3, K Schenk4,5, G Strapazzon4, T Dal Cappello4, H Gatterer4,6, M Palma4, M Erckert7, L Oberhuber8, B Bliemsrieder9, H Brugger4, P Paal10.
Abstract
PURPOSE: Suspension syndrome describes a potentially life-threatening event during passive suspension on a rope. The pathophysiological mechanism is not fully understood and optimal treatment unknown. We aimed to elucidate the pathophysiology and to give treatment recommendations.Entities:
Keywords: Climbing; Harness hang syndrome; Pathophysiology; Suspension syndrome; Suspension trauma; Treatment
Mesh:
Year: 2019 PMID: 30895459 PMCID: PMC6517360 DOI: 10.1007/s00421-019-04126-5
Source DB: PubMed Journal: Eur J Appl Physiol ISSN: 1439-6319 Impact factor: 3.078
Fig. 1Study design. ScO cerebral oxygen saturation, StO tissue oxygen saturation of the calf muscles, LVEDD left ventricular end-diastolic diameter, LVESD left ventricular end-systolic diameter, SFV superficial femoral vein, BIA body impedance analysis
Criteria for interruption of the suspension phase
| Participant wishes to interrupt the study |
| Predefined maximal duration of 60 min reached |
| Heart rate < 35 or > 160 bpm |
| Systolic blood pressure < 90 mmHg or > 200 mmHg |
| Glasgow coma scale ≤ 13 |
| Decrease of cerebral oxygen saturation > 25% from baseline |
| Pre-syncopal signs and symptoms, i.e., dizziness, light-headedness, pale skin, a cold and clammy sweat, blurred vision and nausea |
Bpm beats per minute
Fig. 2Cases with and without pre-syncope, divided in climbing and no-climbing prior to the suspension phase
P values for fixed effects considered in the linear mixed model
| Fixed effect | Dependent variable of linear mixed modela | |||||||
|---|---|---|---|---|---|---|---|---|
| HR | SBP | SV | StO2 | ScO2 | SFV | LVEDD | LVESD | |
| Intercept | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| Time | < 0.001 | < 0.001 | < 0.001 | < 0.001 | 0.004 | < 0.001 | 0.001 | 0.047 |
| Climbing | < 0.001 | < 0.001 | 0.648 | 0.828 | 0.607 | 0.581 | 0.109 | 0.678 |
| Pre-syncope | 0.371 | 0.036 | 0.457 | 0.985 | 0.256 | 0.035 | 0.024 | 0.042 |
| Pain | 0.603 | 0.389 | 0.694 | 0.967 | 0.387 | 0.173 | 0.019 | 0.037 |
| Climbing × time | < 0.001 | 0.034 | 0.535 | 0.043 | 0.052 | 0.708 | 0.475 | 0.947 |
| Pre-syncope × time | 0.007 | < 0.001 | 0.111 | 0.487 | 0.071 | 0.224 | 0.548 | 0.202 |
| Pain × time | 0.256 | 0.250 | 0.696 | 0.943 | 0.884 | 0.250 | 0.379 | 0.214 |
HR heart rate, SBP systolic blood pressure, SV stroke volume, StO tissue oxygen saturation, ScO cerebral oxygen saturation, SFV diameter of the superficial femoral vein, LVEDD left ventricular end-diastolic diameter, LVESD left ventricular end-systolic diameter
aFor all models the covariance structure for the residuals is AR(1), except for SBP and LVEDD compound symmetry
Fig. 3Progress of StO2 and SFV during suspension test. Black colour represents progresses without climbing before the test and red colour represents progresses with previous climbing. The two thicker lines represent the mean values of the two groups and the black vertical dashed line at the start of post-hanging phase. BLsu baseline value in supine position, BLst baseline value in standing position, last last measure before end of the test
Fig. 4Progress of HR, SBP, SV and LVD during suspension test. Black colour represents progresses without climbing before the test and red colour represents progresses with previous climbing. The two thicker lines represent the mean values of the two groups and the black vertical dashed line at the start of post-hanging phase. BLsu baseline value in supine position, BLst baseline value in standing position, last last measure before end of the test
Fig. 5In an unconscious person suspended in a sit harness, the attachment point of the rope, located at the level of the hips will represent the highest point